Hoth Therapeutics Shares Rise on Expanded Trial for Skin Toxicities Treatment

MT Newswires Live09-06

Hoth Therapeutics (HOTH) shares rose 61% in recent Thursday trading on plans to expand the company's first-in-human phase 2a clinical trial of HT-001 for the treatment of skin toxicities related to epidermal growth factor receptor inhibitors.

The phase 2a dose-ranging study will assess the effectiveness, safety and tolerability of topical HT-001 for addressing skin toxicities caused by EGFRi, the company said Thursday in statement.

The company received institutional review board approval from the Montefiore Medical Center and Dana-Farber Cancer Institute to proceed with the trial.

Price: 1.12, Change: +0.43, Percent Change: +61.24

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2465052050?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-06 01:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2465052050","market":"sg","top_or_hot":-1,"title":"Hoth Therapeutics Shares Rise on Expanded Trial for Skin Toxicities Treatment","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> (HOTH) shares rose 61% in recent Thursday trading on plans to expand the company's first-in-human phase 2a clinical trial of HT-001 for the treatment of skin toxicities related to epidermal growth factor receptor inhibitors.</p><p>The phase 2a dose-ranging study will assess the effectiveness, safety and tolerability of topical HT-001 for addressing skin toxicities caused by EGFRi, the company said Thursday in statement.</p><p>The company received institutional review board approval from the Montefiore Medical Center and Dana-Farber Cancer Institute to proceed with the trial.</p><p>Price: 1.12, Change: +0.43, Percent Change: +61.24</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Therapeutics Shares Rise on Expanded Trial for Skin Toxicities Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Therapeutics Shares Rise on Expanded Trial for Skin Toxicities Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-06 01:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hoth Therapeutics (HOTH) shares rose 61% in recent Thursday trading on plans to expand the company's first-in-human phase 2a clinical trial of HT-001 for the treatment of skin toxicities related to ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1167","symbol_name":"电子制造服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2465052050","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2465052050","pubTimestamp":1725555707,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hoth Therapeutics  shares rose 61% in recent Thursday trading on plans to expand the company's first-in-human phase 2a clinical trial of HT-001 for the treatment of skin toxicities related to epidermal growth factor receptor inhibitors.The phase 2a dose-ranging study will assess the effectiveness, safety and tolerability of topical HT-001 for addressing skin toxicities caused by EGFRi, the company said Thursday in statement.The company received institutional review board approval from the Montefiore Medical Center and Dana-Farber Cancer Institute to proceed with the trial.Price: 1.12, Change: +0.43, Percent Change: +61.24","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1167":"电子制造服务","BK4007":"制药","01611":"新火科技控股","HOTH":"Hoth Therapeutics"},"translate_title":"Hoth Therapeutics股价因皮肤毒性治疗试验扩大而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":1,"01611":0.88},"content_text":"Hoth Therapeutics (HOTH) shares rose 61% in recent Thursday trading on plans to expand the company's first-in-human phase 2a clinical trial of HT-001 for the treatment of skin toxicities related to epidermal growth factor receptor inhibitors.The phase 2a dose-ranging study will assess the effectiveness, safety and tolerability of topical HT-001 for addressing skin toxicities caused by EGFRi, the company said Thursday in statement.The company received institutional review board approval from the Montefiore Medical Center and Dana-Farber Cancer Institute to proceed with the trial.Price: 1.12, Change: +0.43, Percent Change: +61.24","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2465052050"}